Stay updated with breaking news from Revibe Connect. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Healio’s most-viewed psychiatry stories in February highlight a study on antidepressant combination therapies, updates in ADHD treatments and the pandemic’s impact on those with mood and anxiety disorders. Combination therapy that included an antagonist of presynaptic alpha2-autoreceptors appeared effective and safe for patients with depression who did not respond to monotherapy,
/PRNewswire/ -- Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining...
– FokusRx™ feasibility study demonstrates positive results – – Company plans to initiate Phase 3 trial with FokusRx in ADHD in the second half of 2022 –...
/PRNewswire/ -- Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining...
WAKE FOREST —Revibe Technologies will invest in the clinical and regulatory development of its flagship product, Revibe Connect, a digital therapeutic smartwatch device powered by artificial intelligence after closing $3 million in funding led by the Carolina Angel Network. To lead this effort, company founder Rich Brancaccio will transition from the role of CEO to the role of chief innovation officer, and the company will hire Joseph Koziak as its new CEO, it announced in a statement. The company’s product aims to assist children with autism and attention deficit hyperactivity disorder...